Hyperhomocysteinemia and high doses of nilotinib favor cardiovascular events in chronic phase Chronic Myelogenous Leukemia patients
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:101 |
|---|---|
| Enthalten in: |
Haematologica - 101(2016), 3 vom: 04. März, Seite e86-90 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fossard, Gaëlle [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.01.2017 Date Revised 14.01.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3324/haematol.2015.135103 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM255269323 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM255269323 | ||
| 003 | DE-627 | ||
| 005 | 20231224174135.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3324/haematol.2015.135103 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0850.xml |
| 035 | |a (DE-627)NLM255269323 | ||
| 035 | |a (NLM)26635034 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fossard, Gaëlle |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hyperhomocysteinemia and high doses of nilotinib favor cardiovascular events in chronic phase Chronic Myelogenous Leukemia patients |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.01.2017 | ||
| 500 | |a Date Revised 14.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a BCR-ABL | |
| 650 | 4 | |a cardiovascular events | |
| 650 | 4 | |a chronic phase CML | |
| 650 | 4 | |a homocysteine | |
| 650 | 4 | |a nilotinib | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Cholesterol, HDL |2 NLM | |
| 650 | 7 | |a Pyrimidines |2 NLM | |
| 650 | 7 | |a Triglycerides |2 NLM | |
| 650 | 7 | |a Homocysteine |2 NLM | |
| 650 | 7 | |a 0LVT1QZ0BA |2 NLM | |
| 650 | 7 | |a Imatinib Mesylate |2 NLM | |
| 650 | 7 | |a 8A1O1M485B |2 NLM | |
| 650 | 7 | |a nilotinib |2 NLM | |
| 650 | 7 | |a F41401512X |2 NLM | |
| 700 | 1 | |a Blond, Emilie |e verfasserin |4 aut | |
| 700 | 1 | |a Balsat, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Morisset, Stéphane |e verfasserin |4 aut | |
| 700 | 1 | |a Giraudier, Stéphane |e verfasserin |4 aut | |
| 700 | 1 | |a Escoffre-Barbe, Martine |e verfasserin |4 aut | |
| 700 | 1 | |a Labussière-Wallet, Hélène |e verfasserin |4 aut | |
| 700 | 1 | |a Heiblig, Maël |e verfasserin |4 aut | |
| 700 | 1 | |a Bert, Arthur |e verfasserin |4 aut | |
| 700 | 1 | |a Etienne, Madeleine |e verfasserin |4 aut | |
| 700 | 1 | |a Drai, Jocelyne |e verfasserin |4 aut | |
| 700 | 1 | |a Sobh, Mohamad |e verfasserin |4 aut | |
| 700 | 1 | |a Redonnet-Vernhet, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Lega, Jean-Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Mahon, François-Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Etienne, Gabriel |e verfasserin |4 aut | |
| 700 | 1 | |a Nicolini, Franck Emmanuel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Haematologica |d 1947 |g 101(2016), 3 vom: 04. März, Seite e86-90 |w (DE-627)NLM000081892 |x 1592-8721 |7 nnns |
| 773 | 1 | 8 | |g volume:101 |g year:2016 |g number:3 |g day:04 |g month:03 |g pages:e86-90 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3324/haematol.2015.135103 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 101 |j 2016 |e 3 |b 04 |c 03 |h e86-90 | ||